• BD focuses strategically on achieving growth in three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences:
  

  BD Medical is among the world’s leading suppliers of medical devices. BD built the first-ever manufacturing facility in the U.S. to produce syringes and needles in 1906 and has been the leading innovator in injection- and infusion-based drug delivery ever since.
  
  BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostic specimens and of instrumentation for quick, accurate analysis for a broad range of microbiology and infectious disease testing, including the growing problem of healthcare-associated infections. The segment is composed of two operating units: Preanalytical Systems, a world leader in blood collection devices, and Diagnostic Systems, a leader in microbiology testing products and molecular assays.
  
  BD Biosciences is one of the world’s leading businesses bringing innovative tools to life scientists, clinical researchers and clinicians. Our customers are involved in basic research, drug and vaccine discovery and development, biopharmaceutical production, clinical trials, diagnostic testing and disease management.

• Revenues rose to $6.36 billion for the fiscal year ended September 30, 2007.  BD generates just over 50 percent of its revenues outside the United States.
  
  
• In FY2007, BD invested $360 million in research and development.
  
  
• BD was founded as a partnership in 1897, incorporated in 1906. BD became a publicly held company in 1962. The stock is traded on the New York Stock Exchange with the symbol BDX.
  
  
• BD employs approximately 28,000 associates worldwide in 184 locations in nearly 50 countries.
  
  
• The company's website is www.bd.com

Return to Top